(PFE) Pfizer - Overview
Stock: Vaccines, Antibiotics, Oncology, Cardiovascular, Biologics
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 7.10% |
| Yield on Cost 5y | 6.34% |
| Yield CAGR 5y | 2.47% |
| Payout Consistency | 97.9% |
| Payout Ratio | 58.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 29.2% |
| Relative Tail Risk | -5.39% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.44 |
| Alpha | 0.56 |
| Character TTM | |
|---|---|
| Beta | 0.500 |
| Beta Downside | 0.563 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.16% |
| CAGR/Max DD | -0.21 |
Description: PFE Pfizer January 27, 2026
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets and distributes a broad portfolio of biopharmaceutical products worldwide, spanning cardiovascular-migraine treatments (Eliquis, Nurtec ODT/Vydura), infectious-disease vaccines (Prevnar, Abrysvo, Trumenba), COVID-19 solutions (Comirnaty, Paxlovid), biosimilars (Xeljanz, Enbrel), and specialty therapies for amyloidosis, hemophilia, endocrine and sickle-cell diseases. The company also operates a contract-manufacturing business and serves a diverse customer base that includes wholesalers, hospitals, pharmacies and government agencies, while maintaining strategic collaborations with firms such as Bristol-Myers Squibb, Astellas, Merck KGaA, BioNTech and AI-focused partner Boltz, PBC.
Key recent metrics: • FY 2023 total revenue was $100.3 billion, down 2 % YoY as COVID-19 product sales fell ≈ $4 billion, while core franchise growth (e.g., Eliquis +5 % and Prevnar +3 %) partially offset the decline. • Q1 2024 adjusted earnings per share (EPS) came in at $1.15, beating consensus by 8 % and reflecting a 12 % YoY increase in R&D efficiency (R&D spend $9.5 billion, 9.5 % of revenue). • The global biopharma sector is projected to grow 6 % CAGR through 2028, driven by aging populations and rising demand for specialty biologics-trends that align with Pfizer’s focus on high-margin immunology and oncology pipelines.
For a deeper, data-driven assessment of Pfizer’s valuation dynamics, you may find the ValueRay platform’s analytical tools useful.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 7.77b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.42 > 1.0 |
| NWC/Revenue: 16.50% < 20% (prev 11.57%; Δ 4.93% < -1%) |
| CFO/TA 0.03 > 3% & CFO 6.36b > Net Income 7.77b |
| Net Debt (61.71b) to EBITDA (15.10b): 4.09 < 3 |
| Current Ratio: 1.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.69b) vs 12m ago -0.30% < -2% |
| Gross Margin: 70.33% > 18% (prev 0.67%; Δ 6967 % > 0.5%) |
| Asset Turnover: 29.65% > 50% (prev 29.82%; Δ -0.17% > 0%) |
| Interest Coverage Ratio: 3.20 > 6 (EBITDA TTM 15.10b / Interest Expense TTM 2.67b) |
Altman Z'' 3.33
| A: 0.05 (Total Current Assets 46.92b - Total Current Liabilities 36.60b) / Total Assets 208.73b |
| B: 0.58 (Retained Earnings 121.15b / Total Assets 208.73b) |
| C: 0.04 (EBIT TTM 8.53b / Avg Total Assets 211.06b) |
| D: 0.80 (Book Value of Equity 92.80b / Total Liabilities 115.64b) |
| Altman-Z'' Score: 3.33 = A |
What is the price of PFE shares?
Over the past week, the price has changed by +2.95%, over one month by +8.83%, over three months by +13.33% and over the past year by +13.03%.
Is PFE a buy, sell or hold?
- StrongBuy: 7
- Buy: 2
- Hold: 15
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the PFE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.7 | 5.5% |
| Analysts Target Price | 28.7 | 5.5% |
| ValueRay Target Price | 29.9 | 9.7% |
PFE Fundamental Data Overview February 07, 2026
P/E Forward = 9.2336
P/S = 2.4068
P/B = 1.6408
P/EG = 3.7725
Revenue TTM = 62.58b USD
EBIT TTM = 8.53b USD
EBITDA TTM = 15.10b USD
Long Term Debt = 56.55b USD (from longTermDebt, two quarters ago)
Short Term Debt = 4.30b USD (from shortTermDebt, two quarters ago)
Debt = 61.71b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 61.71b USD (using Total Debt 61.71b, CCE unavailable)
Enterprise Value = 212.33b USD (150.61b + Debt 61.71b - (null CCE))
Interest Coverage Ratio = 3.20 (Ebit TTM 8.53b / Interest Expense TTM 2.67b)
EV/FCF = 46.44x (Enterprise Value 212.33b / FCF TTM 4.57b)
FCF Yield = 2.15% (FCF TTM 4.57b / Enterprise Value 212.33b)
FCF Margin = 7.31% (FCF TTM 4.57b / Revenue TTM 62.58b)
Net Margin = 12.42% (Net Income TTM 7.77b / Revenue TTM 62.58b)
Gross Margin = 70.33% ((Revenue TTM 62.58b - Cost of Revenue TTM 18.57b) / Revenue TTM)
Gross Margin QoQ = 69.97% (prev 74.95%)
Tobins Q-Ratio = 1.02 (Enterprise Value 212.33b / Total Assets 208.73b)
Interest Expense / Debt = 1.15% (Interest Expense 711.0m / Debt 61.71b)
Taxrate = 21.0% (US default 21%)
NOPAT = 6.74b (EBIT 8.53b * (1 - 21.00%))
Current Ratio = 1.28 (Total Current Assets 46.92b / Total Current Liabilities 36.60b)
Debt / Equity = 0.66 (Debt 61.71b / totalStockholderEquity, last quarter 93.10b)
Debt / EBITDA = 4.09 (Net Debt 61.71b / EBITDA 15.10b)
Debt / FCF = 13.50 (Net Debt 61.71b / FCF TTM 4.57b)
Total Stockholder Equity = 91.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.68% (Net Income 7.77b / Total Assets 208.73b)
RoE = 8.52% (Net Income TTM 7.77b / Total Stockholder Equity 91.23b)
RoCE = 5.77% (EBIT 8.53b / Capital Employed (Equity 91.23b + L.T.Debt 56.55b))
RoIC = 4.45% (NOPAT 6.74b / Invested Capital 151.63b)
WACC = 5.77% (E(150.61b)/V(212.33b) * Re(7.76%) + D(61.71b)/V(212.33b) * Rd(1.15%) * (1-Tc(0.21)))
Discount Rate = 7.76% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.34%
[DCF Debug] Terminal Value 83.67% ; FCFF base≈6.68b ; Y1≈5.30b ; Y5≈3.54b
Fair Price DCF = 8.29 (EV 108.83b - Net Debt 61.71b = Equity 47.11b / Shares 5.69b; r=5.90% [WACC]; 5y FCF grow -24.64% → 2.90% )
EPS Correlation: -41.15 | EPS CAGR: -21.29% | SUE: 0.90 | # QB: 9
Revenue Correlation: -58.19 | Revenue CAGR: -9.63% | SUE: 0.37 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.73 | Chg30d=-0.020 | Revisions Net=-2 | Analysts=15
EPS current Year (2026-12-31): EPS=2.98 | Chg30d=-0.015 | Revisions Net=-6 | Growth EPS=-7.4% | Growth Revenue=-2.4%
EPS next Year (2027-12-31): EPS=2.85 | Chg30d=-0.039 | Revisions Net=-4 | Growth EPS=-4.5% | Growth Revenue=-3.4%